ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1772

Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice

Arisa Yaekura1, Kanta Morii 2, Yuto Oketani 3, Ikumi Okumura 2, Kenta Kaneshiro 4, Kohsuke Yoshida 2, Yoshiko Kawasaki 5, Nao Shibanuma 5, Yoshitada Sakai 6 and Akira Hashiramoto 2, 1Kobe University Graduate School of Health Sciences, Kawanishi, Hyogo, Japan, 2Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, 3Kobe University Graduate School of Health Sciences, Himeji, Hyogo, Japan, 4Kobe University Graduate School of Health Sciences, Osaka, Osaka, Japan, 5Kobe Kaisei Hospital, Kobe, Hyogo, Japan, 6Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: animal models and treatment options, cytokines, Janus kinase (JAK), pharmacotherapy, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: 4M093: RA – Animal Models (1770–1775)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Diurnal variations are observed in symptoms of rheumatoid arthritis (RA). Among them, “morning stiffness of joints” is closely reflects the daily medical condition of RA patients. The diurnal variation is also present in the production of inflammatory cytokines that interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) or interferon-gamma (IFN-γ) show peak concentrations in sera of RA patients during mid night, and similarly, those of collagen-induced arthritis (CIA) mice are reported to increase from morning to evening. A Janus kinase (JAK) inhibitor Baricitinib, orally administrated once a day, competitively inhibits phosphorylation of JAK1/2 bound of type 1/2 cytokine receptors, and suppresses productions of wide range of inflammatory cytokines derived from JAK/ signal transducers and activator of transcription (STAT) pathway. As reference to a recent report that chronotherapy using modified-release prednisone effectively suppresses “morning stiffness” of RA patients, in this study, differences in efficacy according to oral administration time of Baricitinib, targeting peaks of cytokine secretion, were examined in CIA mice.

Methods: CIA mice were administered a dose of 3 mg/kg of Baricitinib once a day at zeitgeber time (ZT) 0 or ZT12 for 21 days. Mice paws and ankles were scored on a scale from 0-4, as the cumulative value for all paws with a maximum possible score of 16, every third day. On day21, Hind limbs were examined by hematoxylin eosin staining. Hepatic proteins at ZT2, 6, 10, 14, 18 and 22 were analyzed for phosphorylation of STAT3 by western blotting. Splenic lymphocytes were isolated at ZT2, 6, 10, 14, 18 and 22 to measure expressions of IL-1β, IL-6, IL-17A, TNF, IFN-γ and Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) by Real-time PCR.

Results: Arthritis score of ZT0/12 group decreased from day3 as compared to the untreated group, and those of ZT12 group rose significantly higher than those of ZT0 group from day12 (Fig. 1a). Joint destructions with synovial hyperplasia were observed in untreated group and ZT12 treated group, while those were suppressed in ZT0 group (Fig. 1b). In CIA mice, STAT3 was highly phosphorylated from ZT22 to ZT10 (Fig. 2a), and it was suppressed in ZT0 group (ZT2) (Fig. 2b). The expressions of IL-1β, IL-6, TNF, and GM-CSF reached maximum levels at ZT2 in untreated group, and that of IFN-γ reached maximum level at ZT22. At ZT2, the expressions of IL-6, IFN-γ, TNF and GM-CSF in ZT0 treated group were significantly decreased as compared to untreated mice, whereas those of ZT12 group were not. The expressions of IL-1β, IL-17A in lymphocytes were significantly decreased by Baricitinib treatment as compared to untreated group (Fig. 3).

Conclusion: Administration of Baricitinib at ZT0 significantly attenuated the progression of arthritis in CIA mice. Results show that chronotherapy targeting cytokine secretions is far more effective than previously considered, and clinical application of chronotherapy using Baricitinib can be expected to enhance the drug efficacy by appropriate administration.

Fig. 1 Arthritis score of ZT0/12 group decreased from day3 as compared to the untreated group, and those of ZT12 group rose significantly higher than those of ZT0 group from day12 -a-. Joint destructions with synovial hyperplasia were observed in untreated group and ZT12 treated group, while those were suppressed in ZT0 group -b-.

Fig. 2 In CIA mice, STAT3 was highly phosphorylated from ZT22 to ZT10 -a-. Phosphorylation of STAT3 was suppressed in ZT0 group at ZT2 -b-.

Fig. 3 RNA expression levels in spleen at ZT2.


Disclosure: A. Yaekura, None; K. Morii, None; Y. Oketani, None; I. Okumura, None; K. Kaneshiro, None; K. Yoshida, None; Y. Kawasaki, None; N. Shibanuma, None; Y. Sakai, None; A. Hashiramoto, None.

To cite this abstract in AMA style:

Yaekura A, Morii K, Oketani Y, Okumura I, Kaneshiro K, Yoshida K, Kawasaki Y, Shibanuma N, Sakai Y, Hashiramoto A. Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/chronotherapy-using-baricitinib-attenuates-collagen-induced-arthritis-in-mice/. Accessed March 8, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chronotherapy-using-baricitinib-attenuates-collagen-induced-arthritis-in-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.